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Abstract
Objective—We aimed to systematically review available literature linking adipokines to
gestational diabetes mellitus (GDM) for a comprehensive understanding of the roles of adipokines
in the development of GDM.
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Methods—We searched PubMed/MEDLINE and EMBASE databases for published studies on
adipokines and GDM through October 21, 2014. We included articles if they had a prospective
study design (i.e., blood samples for adipokines measurement were collected before GDM
diagnosis). Random-effects models were used to pool the weighted mean differences comparing
levels of adipokines between GDM cases and non-GDM controls.
Results—Of 1,523 potentially relevant articles, we included 25 prospective studies relating
adipokines to incident GDM. Our meta-analysis of nine prospective studies on adiponectin and
eight prospective studies on leptin indicated that adiponectin levels in the first or early second
trimester of pregnancy were 2.25 μg/ml lower (95% CI: 1.75–2.75), whereas leptin levels were
7.25 ng/ml higher (95% CI 3.27–11.22), among women who later developed GDM than women
who did not. Prospective data were sparse and findings were inconsistent for visfatin, retinol
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binding protein (RBP-4), resistin, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and
vaspin. We did not identify prospective studies for several novel adipokines, including chemerin,
apelin, omentin, or adipocyte fatty acid-binding protein. Moreover, no published prospective
studies with longitudinal assessment of adipokines and incident GDM were identified.
Conclusion—Adiponectin levels in the first or second trimester of pregnancy are lower among
pregnant women who later develop GDM than non-GDM women, whereas leptin levels are
higher. Well-designed prospective studies with longitudinal assessment of adipokines during
pregnancy are needed to understand the trajectories and dynamic associations of adipokines with
GDM risk.
Keywords
gestational diabetes mellitus; adipokines; adiponectin; leptin
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1. INTRODUCTION
Gestational diabetes mellitus (GDM), a common pregnancy complication, is defined as
glucose intolerance with onset or first recognition during pregnancy [1]. Approximately 7%
(ranging from 1% to 14%) of all pregnancies in the United States are complicated by GDM,
resulting in more than 200,000 cases annually [1]. Women with GDM have an increased risk
for prenatal morbidity and a considerably elevated risk for type 2 diabetes mellitus (T2DM)
after pregnancy [1]. Furthermore, the offspring of women with GDM are more likely to be
obese and have impaired glucose tolerance and T2DM in their early adulthood [2].
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Adiposity is an important modifiable risk factor for the development of GDM [3], although
mechanisms linking excess adiposity to elevated risk of GDM are not completely
understood. Adipose tissue is not only involved in energy storage but also functions as an
active endocrine organ [4]. Recent evidence points to a crucial role of specific hormones and
cytokines (i.e., adipokines) secreted by the adipose tissue. A major breakthrough in
understanding the link between adiposity and glucose intolerance has come from the
demonstration of crosstalk between adipose tissue and other insulin target tissues such as
skeletal muscles and the liver [5]. Such crosstalk is mediated by a number of molecules that
are secreted by adipocytes [4]. Among those identified to date are adiponectin, leptin,
resistin, retinol binding protein 4 (RBP4), and tumor necrosis factor-α (TNF-α), etc. In
concert, these adipokines are believed to adapt metabolic fluxes to the amount of stored
energy. Dysregulation of this network is a critical factor in the deterioration of insulin
sensitivity [4, 6].
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Despite the promising role of these adipokines in glucose homeostasis, their roles in the
development of GDM remain to be elucidated. Although there have been a number of
human studies on adipokines and GDM during the past decades, inferences have been
hindered due to significant heterogeneities in these studies concerning design, population
characteristics, assay methods, timing of blood sample collection, and definition/diagnosis
of GDM. Moreover, the majority of previous studies had a small sample size that may lead
to false positive or negative findings. We aimed to systematically review the current
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literature and quantitatively synthesize prospective data regarding adipokines and GDM risk,
and to identify important data gaps.

2. MATERIALS AND METHODS
When conducting the study, we adhered to the Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) guidelines [7].
2.1 Literature search and study selection
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We conducted a comprehensive electronic search of PubMed and EMBASE databases for
literature on adipokines and GDM through October 21, 2014. To maximize the coverage in
our literature search, we used a combination of free text (e.g., gestational diabetes) and
subheadings from MeSH (e.g., “Diabetes, Gestational”[Mesh]) or EMTREE terms (e.g.,
‘pregnancy diabetes mellitus’/exp). In addition to using the generic term for adipokines, we
also specifically named each key adipokine (e.g., adiponectin, leptin, resistin, etc.) when
conducting the literature search. Detailed search terms are listed in the Supplementary
Materials. We restricted the literature search to English language. All reference lists from
the main articles and relevant reviews were hand searched to identify additional studies.
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Figure 1 summarizes the process of literature search and study selection. Articles were
eligible for inclusion if they had a prospective study design (i.e., blood samples for
adipokines measurement were collected before the diagnosis of GDM, typically before 24
weeks of gestational age), and they compared adipokine levels measured in pregnant women
who later developed GDM with women with normoglycemic pregnancies. We excluded the
following types of articles: review articles or editorials, non-human studies (i.e., cell culture
or animal studies), studies that did not include GDM as the primary concern, and studies that
did not evaluate adipokine levels. We also excluded articles that combined GDM with
impaired glucose tolerance or previous cases of type 1 diabetes or T2DM. Disagreement
about eligibility was settled by consensus between all authors.
2.2 Data extraction
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The following data were extracted from each eligible article: the first author’s name, year of
publication, sample size, number of GDM cases, ethnicity, study design, time for blood
samples collected for adipokine measurement, method of adipokine measurement, time and
criteria for GDM diagnosis, and mean and standard deviation (SD) of adipokine levels
among GDM cases and the comparison group. When necessary, we contacted the
corresponding authors of the original articles by email to request relevant data or
information. We also extracted odds ratios, risk ratios, and 95% confidence intervals if they
were available. If multiple articles were published using data from the same cohort, we
extracted the report with the information most relevant to the analysis.
2.3 Data synthesis and statistical analysis
To quantitatively summarize the available data, we conducted meta-analyses for adipokines
with more than five independent studies. We calculated weighted mean differences (WMDs)
in adipokine levels for each of the included studies, and pooled them in the meta-analysis
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using random-effects model [8]. We also calculated standardized mean differences (SMDs)
when different units across studies were used for a certain adipokine. When means and SDs
were not reported in the full-text article, we approximated them using the median and
interquartile range. When applicable, the standard error of the mean was transformed into
SD. Forest plots and funnel plots were used for visualizing the overall effect size and
evaluating publication bias, respectively. The probability of publication bias was also
statistically assessed using Egger regression asymmetry test [9].
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We assessed between-study heterogeneity using the χ2-based Cochran’s Q statistic and the
I2 metric (I2 value of 25, 50, and 75% were considered as low, medium, and high
heterogeneity, respectively) [10]. Potential sources of between-study heterogeneity were
also investigated by a priori-defined stratification analyses. Specifically, we stratified the
included studies by geographical location, sample size, time for determination of exposure
(i.e., adipokines) and outcome (i.e., GDM), assay methods for adipokines, and diagnostic
criteria for GDM. A formal meta-regression was also performed by the aforementioned
factors, but the potential for robust conclusions from meta-regression analyses may be very
limited [11], because the number of included studies was small for some adipokines.
Sensitivity analyses were performed by omitting one study at a time and computing the
pooled the effect size of the remaining studies to evaluate whether the results were affected
markedly by a single study. All statistical analyses were performed using Stata software
version 11.0 (Stata Corp, College Station, TX, USA).

3. RESULTS
3.1 Characteristics of the included studies
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Our initial literature search identified 1,523 articles from PubMed/MEDLINE and EMBASE
databases. After applying the inclusion and exclusion criteria, 25 prospective studies [12–
36] on eight adipokines were ultimately included in the systematic review (Figure 1). These
adipokines were adiponectin, leptin, visfatin, RBP-4, resistin, TNF-α, IL-6, and vaspin.
Supplementary Table 1 summarizes the potential functions of these adipokines that may link
them to the pathogenesis of GDM. In general, the number of prospective studies on GDM
risk and these adipokines, except adiponectin and leptin, was sparse. We did not identify
prospective studies relating several novel adipokines, such as chemerin, apelin, omentin, or
adipocyte fatty acid-binding protein, to GDM risk.
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Table 1 and Table 2 show characteristics of the 13 prospective studies about adiponectin and
nine prospective studies about leptin, respectively. Overall, the reporting of the included
studies was generally well described with sufficient details concerning key parameters such
as the number of cases and controls, adipokine measurements (time for blood collection and
assay method), and GDM diagnosis (time and criteria).
Among the 13 included studies for adiponectin, six studies were conducted in Europe, four
in North America, two in Asia and one in Australia. Five studies used the criteria proposed
by Carpenter and Coustan or the American Diabetes Association (ADA) (these two criteria
used the same procedure and cut points) for the diagnosis of GDM, three studies used the
World Health Organization (WHO) criteria, three studies used the recently proposed criteria
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by the International Association of the Diabetes and Pregnancy Study Groups (IADPSG),
and two used local criteria. GDM was usually diagnosed during the 24–28 weeks of
gestation in these studies, with one exception. Blood samples for adiponectin measurement
were collected at 5–20 weeks of gestation. No substantial differences were observed in the
assay methods applied to measure adiponectin levels. The majority of included studies used
enzyme immunoassays (EIA), while others employed radioimmunoassay (RIA). Several
studies reported quality control measurements for adiponectin [15, 19, 20, 22, 23, 36], and
the intra-assay and inter-assay coefficients of variation were acceptable (all < 10%).
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Of the nine studies for leptin, three studies were conducted in North America, two in the
Europe, two in Asia, one in Australia, and one in Mexico. GDM was usually diagnosed
during the 24–28 weeks of gestation. The definition used for GDM was the criteria proposed
by Carpenter and Coustan or the ADA in three studies, the IADPSG criteria in two studies,
the National Diabetes Data Group criteria in one study, and local criteria in another two
studies. Blood samples for leptin measurement were collected at 5–20 weeks of gestation.
No substantial differences were observed in the methodology applied to assays; five studies
used RIA, while the other four studies used EIA. Several studies reported quality control
measurements for leptin [14, 16, 19, 26, 36], and the intra-assay and inter-assay coefficients
of variation were acceptable (all < 10%).
3.2 Quantitative assessment of summary statistics
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3.2.1 Adiponectin—Adiponectin was the most widely studied adipokines in relation to
GDM, and the available studies yielded relatively consistent results across different
populations. Among the included studies, three studies reported a comparable value but
different unit of adiponectin (i.e., ng/ml in two studies [18, 21] and mg/ml in the other study
[34]) compared with others (i.e., μg/ml), and thus the reported values were unreasonably
high or low after converting. We did not get confirmation from the original authors by
email. Thus, to be conservative, we did not include these studies in the main analysis which
calculated the pooled WMD. Instead, we included them in a sensitivity analysis using
pooled SMD as the metric. In another study [36], adiponectin levels were reported as
geometric means and ratios, without values in the absolute scale, and therefore it was
omitted in the meta-analysis. Our meta-analysis of the other nine studies showed that
adiponectin levels in the first or early second trimester were significantly lower in women
who later developed GDM compared to women who later did not, yet with significant
between-study heterogeneity (random-effects pooled WMD [95% CI], −2.25 [−2.75 to
−1.75] μg/ml; I2 = 86%; Figure 2). Egger test for publication bias did not reach statistical
significance (P = 0.49).
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In stratified analyses (Supplementary Table 2), the pooled WMDs were not differentiated
appreciably by geographical location (North America versus others), sample size (< 100
versus ≥100), average timing of blood samples collection for adiponectin measurement (first
versus second trimester), assay methods for adiponectin measurement (EIA versus RIA),
and diagnostic criteria for GDM (WHO criteria versus others). We did not stratify by time
for GDM diagnosis because almost all included studies reported the diagnosis at 24–28
weeks of gestation. Meta-regression analysis including the above variables in the model also
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did not identify significant contributors to the source of heterogeneity. Sensitivity analysis
by omitting one study at a time did not alter the results (Supplementary Figure 1). In
addition, we calculated the pooled SMD which allows including the results from all studies
regardless of units. The pooled random-effects SMD (95% CI) was −1.20 (−1.63 to −0.78)
(Supplementary Figure 2).
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3.2.2 Leptin—Among the nine studies, one study [36] reported leptin adiponectin levels as
geometric means and ratios, without values in the absolute scale, and therefore it was
omitted in the meta-analysis. A meta-analysis of the remaining eight prospective studies
showed that leptin levels in the first or early second trimester were significantly higher in
women who later developed GDM compared to women who later did not, yet with
significant between-study heterogeneity (random-effects WMD [95% CI], 7.25 [3.27 to
11.22] ng/ml; I2 = 94%; Figure 3). Egger test for publication bias did not provide evidence
of significant effect (P = 0.41).
Similar to adiponectin, there was no evidence of heterogeneity in pooled WMDs for leptin
levels by average timing of blood collection for leptin measurement (first versus second
trimester), assay methods for leptin measurement (EIA versus RIA), and diagnostic criteria
for GDM (Carpenter and Coustan criteria versus others) (Supplementary Table 3).
Sensitivity analysis by omitting one study at a time did not alter the results materially
(Supplementary Figure 3).
3.3 Findings of adipokines not suitable for a pooling of summary statistics
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We did not pool studies that investigated visfatin, RBP-4, resistin, TNF-α, interleukin-6
(IL-6), or vaspin, because too few independent prospective studies have been published on
these adipokines. Findings on their association with GDM risk have been conflicting (Table
3). For instance, three studies have been conducted about RBP-4 levels and GDM risk [28,
29, 32]. Although a significant association was reported in a U.S. population [29], there was
no significant association in other studies from UK [32] and China [28]. Conflicting results
were also reported in the four studies about TNF-α levels and risk of GDM, with one study
reporting a significant association [18] while another two reporting no significant
association [12, 19, 35]. Recently, adipocyte fatty acid-binding protein (AFABP) has been
suggested to be a probable candidate involved in the pathophysiology of GDM [37].
However, no prospective study has conducted so far on the association between AFABP and
GDM. The only study, which was cross-sectional, reported an elevated AFABP level in
women with GDM as compared with healthy pregnant controls [38].
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4. DISCUSSION
In this systematic review and quantitative analysis of available data regarding adipokines
and GDM, we observed that adiponectin levels in the first or second trimester of pregnancy
are lower among pregnant women who later develop GDM than non-GDM women, whereas
leptin levels are higher. Prospective data were sparse and findings were inconsistent for
visfatin, RBP-4, resistin, TNF-α, IL-6, and vaspin. We did not identify prospective studies
for several novel adipokines, including chemerin, apelin, omentin, or AFABP.
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The observed associations of GDM with adiponectin and leptin levels are biologically
plausible. GDM develops when pancreatic β cells of pregnant women are unable to increase
insulin secretion enough to counteract the corresponding fall in tissue sensitivity to insulin
during pregnancy [39]. Adiponectin is a signaling protein that is synthesized and secreted by
adipose tissue and is one of the most abundant plasma proteins in humans [40]. Adiponectin
can reduce ectopic fat storage through stimulating lipid oxidation and inhibiting lipolysis in
adipose tissue [41]. In addition, adiponectin may also display anti-inflammatory properties
by suppressing TNF-α production [42]. Intravenous administration of recombinant
adiponectin in rodent models of insulin resistance restored normal insulin sensitivity [6]. In
humans, adiponectin levels were inversely associated with fasting glucose, insulin, and
insulin resistance [43], and the risk of developing T2DM [44]. Thus, a reduction in
adiponectin levels may be associated with the development of GDM through decreased
insulin sensitivity and attenuated anti-inflammatory capacity.
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In contrast to adiponectin, leptin may contribute to the pathogenesis of GDM through
elevated insulin resistance. Leptin is an adipose tissue-derived hormone that plays a key role
in the regulation of energy intake and energy expenditure. Circulating leptin levels are
elevated with increasing adiposity [45], reflecting a state of leptin resistance [46]. Several
studies have positively associated leptin levels with insulin resistance independent of body
mass index (BMI), whereas other studies suggest that the relationship between leptin levels
and insulin resistance is mainly accounted for by obesity [47, 48]. Elevated leptin levels
were also independently associated with a higher risk of incident GDM [14] and T2DM
[49]. Animal and human studies have demonstrated that a circulating soluble form of the
leptin receptor influences the amount of free versus bound leptin in serum and plays a part in
modulating availability and biological function of leptin [50]. In humans, an increasing BMI
was associated with a lower concentration of soluble leptin receptor, whereas fasting
increased its concentration [51]. Lewandowski et al [52] reported a significantly higher level
of soluble leptin receptor in women with type 1 diabetic pregnancy than women with normal
pregnancy. However, there is no published study on the association between soluble leptin
receptor and GDM.
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Interestingly, there is evidence, although still limited, implicating that the association
between adipokines and GDM may be independent of adiposity measures. For example,
Williams et al [15] have shown a significantly inverse association between adiponectin
levels in early pregnancy and subsequent risk of GDM after controlling for prepregnancy
BMI. Similar results were reported by Lain et al [20] and LaCroix et al [31]. For leptin, Qiu
et al [14] found a linear association between leptin levels in early pregnancy and GDM risk
independent of prepregnancy BMI and other confounders; each 10 ng/mL increase in the
leptin concentration was associated with a 20% higher in GDM risk. These results indicate
that there could be other pathways linking adipokines to the development of GDM, although
BMI is not an accurate measure of adiposity [53]. Future studies using objective measures of
adiposity (e.g., dual-energy X-ray absorptiometry) may help clarify the adipokines-GDM
relations independent of adiposity. Few studies have investigated the interaction between
adiposity measures and adipokines among pregnancy women. No significant interaction
between BMI and adiponectin in association with risk of developing GDM was found in a
nested case-control study among US pregnant women [20]. Similarly, non-significant
Metabolism. Author manuscript; available in PMC 2016 June 01.
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interactions of adiposity measures and adiponectin levels in relation to T2DM risk were
observed in some [54], although not all [55], studies conducted in the general population.
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There are several critical data gaps that require additional research. First, the trajectories and
dynamic associations of adipokines with subsequent risk of GDM remain unclear. Unlike
diabetes among non-pregnant individuals, the dynamic patterns of adipokine levels in
women with GDM are influenced not only by GDM status, but also by the profound and yet
time-dependent metabolic challenges related to pregnancy. Pregnancy is normally associated
with progressive insulin resistance, and there is a two-thirds decrease in insulin sensitivity in
late pregnancy [39]. In parallel with the changes in insulin sensitivity, adipokines exhibit
different dynamic patterns during normal pregnancy [56]. For instance, adiponectin levels
progressively decline [57] while leptin levels progressively increase during pregnancy [58].
Longitudinal studies with blood samples collected at multiple time points before the onset of
GDM (e.g., before pregnancy or during early pregnancy) would provide insights to improve
understanding of the roles of adipokines in the pathogenesis of GDM. No such study was
identified in our systematic review. Second, the causal relation between adipokines and
GDM warrants further investigation. During the past decades, Mendelian randomization
analysis simultaneously considering the triangle associations of genetic variants,
intermediate phenotypes, and disease status has been increasingly utilized to inform causal
inference in observational studies [59]. However, we are not aware of such studies
investigating associations of both adipokine levels and genetic variants relevant to adipokine
levels with GDM risk using Mendelian randomization analysis approach.
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The strengths of this systematic review include comprehensive literature search and
meticulous protocol for study selection and data analysis. There are several limitations. First,
prospective studies of adipokines and GDM risk among non-Caucasian populations are
sparse. This limited the capacity of exploring the adipokines-GDM association by race/
ethnicity groups. Compared with Caucasian women, Asian, Hispanic, and Native American
women have an increased risk of GDM [3]. In addition, the associations between adipokines
and insulin sensitivity varied by race/ethnicity [60]. Future studies among non-Caucasian
populations are warranted. Second, the number of included studies for most adipokines was
small. Even for adiponectin and leptin, the pooled sample size was limited. Thus it may
compromise the statistical power of the meta-analysis. Although the statistical test showed
no indication of publication bias for the two adipokines included in the meta-analysis, we
cannot rule out the possibility of publication bias due to the small number of studies.

5. Conclusions
Author Manuscript

In summary, in this systematic review, we observed that adiponectin levels in the first or
second trimester of pregnancy are lower among pregnant women who later develop GDM
than non-GDM women, whereas leptin levels are higher. Future studies are warranted to
clarify the association of other adipokines and GDM. Moreover, well-designed prospective
studies with longitudinal assessment of adipokines during pregnancy are needed to
understand the trajectories and dynamic associations of adipokines with GDM risk.
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EIA
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interleukin-6
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Flow chart for literature search and study selection
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Figure 2.

Forest plot for mean difference in adiponectin levels (μg/ml) between GDM cases and
controls
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Figure 3.

Forest plot for mean difference in leptin levels (ng/ml) between GDM cases and controls

Author Manuscript
Author Manuscript
Metabolism. Author manuscript; available in PMC 2016 June 01.

Author Manuscript

Author Manuscript
Italy
UK
UK
Italy
Canada
Finland
Canada
UK

Savvidou et al., 2010 [22]

Ferreira et al., 2011 [23]

Ianniello et al., 2013 [33]

LaCroix et al., 2013 [31]

Rasanen et al., 2013 [34]

Guillemette et al., 2014 [35]

Maitland et al., 2014 [36]

106 (29/77)

749 (61/688)

182 (92/90)

445 (38/407)

32 (16/16)

400 (100/300)

372 (124/248)

50 (12/38)

79 (26/53)

59 (30/29)

28 (14/14)

42 (22/20)

111 (41/70)

Participants (Cases/Controls)

16–18 weeks

5–16 weeks

5–13 weeks

6–13 weeks

8–11 weeks

11–13 weeks

11–19 weeks

8–11 weeks

<18 weeks

<16 weeks

11 weeks

14–20 weeks

13 weeks

Time for blood collection

Adiponectin measurement

EIA

RIA

EIA

RIA

EIA

EIA

EIA

EIA

EIA

RIA

EIA

EIA

EIA

Assay method

27–28 wks

24–28 weeks

2nd trimester

24–28 weeks

24–28 weeks

24–28 weeks

24–28 weeks

23–25 weeks

24–28 weeks

24–28 weeks

28 weeks

24–32 weeks

24–28 weeks

Time for diagnosis

IADPSG

IADPSG

ADA 2008

IADPSG

Carpenter and Coustan, 1982

WHO

WHO

Carpenter and Coustan, 1982

WHO

Carpenter and Coustan, 1982

ADIPS

Yang, 2005; Li, 2006

ADA 2002

Diagnostic criteria
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Study Groups; N/A, not available or not reported; RIA, Radioimmunoassay; WHO, World Health Organization.
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26–28 weeks
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Yang, 2005; Li, 2006

Carpenter and Coustan (1982)
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N/A

Carpenter and Coustan (1982)

Diagnostic criteria

Abbreviations: ADA, American Diabetes Association; ADIPS, Australasian Diabetes in Pregnancy Society; EIA, Enzyme Immunoassay; N/A, not available or not reported; NDDG, National Diabetes Data
Group; RIA, Radioimmunoassay.

China

Georgiou et al., 2008 [19]

USA

Qiu et al., 2004 [14]

Gao et al., 2008 [18]
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USA
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Author, year
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Table 3

Author Manuscript

Summary of the results from available prospective studies relating adipokine levels to GDM risk
Adipokines

Number of studies

Results*

Adiponectin

13

↑ 0 study, ↓ 12 studies, ↔ 1 study

Leptin

9

↑ 4 studies, ↓ 0 study, ↔ 5 studies

Visfatin

2

↑ 1 study, ↓ 0 study, ↔ 1 study

RBP-4

3

↑ 1 study, ↓ 0 study, ↔ 2 studies

Resistin

2

↑ 0 study, ↓ 0 study, ↔ 2 studies

TNF-α

4

↑ 1 study, ↓ 0 study, ↔ 3 studies

IL-6

3

↑ 0 study, ↓ 0 study, ↔ 3 studies

Vaspin

1

↑ 1 study, ↓ 0 study, ↔ 0 study

*

↑ positive association, ↓ inverse association, ↔ non-significant difference (p > 0.05)

Author Manuscript

Abbreviations: IL-6, interleukin-6; RBP-4, retinol binding protein-4; TNF-α, tumor necrosis factor-α.
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